Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMGN Amgen	$306.92 -1.5%	$302.51	$253.30 ▼ $346.85	$167.37B	0.53	2.70 million shs	3.04 million shs
BIIB Biogen	$132.03 -3.5%	$141.63	$128.51 ▼ $238.00	$20.03B	0.01	1.30 million shs	1.35 million shs
MRK Merck & Co., Inc.	$87.08 -3.0%	$91.57	$81.04 ▼ $134.63	$219.95B	0.35	11.06 million shs	13.92 million shs
MRNA Moderna	$27.16 -4.2%	$34.43	$26.78 ▼ $170.47	$10.50B	1.86	6.88 million shs	11.63 million shs
PFE Pfizer	$24.53 -3.2%	$26.00	$24.48 ▼ $31.54	$139.09B	0.61	39.05 million shs	54.33 million shs

7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMGN Amgen	-1.49%	+0.02%	-0.37%	+17.76%	+8.44%
BIIB Biogen	-3.52%	-5.12%	-6.03%	-13.66%	-38.54%
MRK Merck & Co., Inc.	-2.97%	-0.92%	-5.59%	-12.47%	-33.49%
MRNA Moderna	-4.20%	-19.76%	-12.27%	-34.68%	-74.28%
PFE Pfizer	-3.27%	-4.05%	-7.21%	-7.56%	-11.46%

Remove Ads

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AMGN Amgen	4.4321 of 5 stars	2.2	4.0	3.3	3.9	3.6	2.5	0.6
BIIB Biogen	4.9047 of 5 stars	4.2	5.0	0.0	3.7	3.5	2.5	1.9
MRK Merck & Co., Inc.	5 of 5 stars	4.3	5.0	5.0	3.9	3.3	3.3	3.8
MRNA Moderna	4.3993 of 5 stars	4.0	1.0	0.0	4.6	2.4	2.5	1.3
PFE Pfizer	4.9844 of 5 stars	3.3	3.0	4.2	4.2	3.3	3.3	3.1

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AMGN Amgen	2.48	Hold	$314.04	2.32% Upside
BIIB Biogen	2.43	Hold	$213.33	61.58% Upside
MRK Merck & Co., Inc.	2.65	Moderate Buy	$117.12	34.50% Upside
MRNA Moderna	2.04	Hold	$59.00	117.23% Upside
PFE Pfizer	2.63	Moderate Buy	$31.92	30.17% Upside

Current Analyst Ratings Breakdown

Latest MRNA, MRK, BIIB, PFE, and AMGN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
3/21/2025	MRNA Moderna	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Underweight ➝ Underweight	$40.00 ➝ $33.00
3/18/2025	PFE Pfizer	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
3/13/2025	MRNA Moderna	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Neutral	$40.00
3/12/2025	PFE Pfizer	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
3/10/2025	PFE Pfizer	Hsbc Global Res Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
3/5/2025	AMGN Amgen	Johnson Rice Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$294.00
3/5/2025	AMGN Amgen	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Underperform ➝ Underperform	$275.00 ➝ $294.00
2/19/2025	MRNA Moderna	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$96.00 ➝ $78.00
2/18/2025	BIIB Biogen	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$138.00 ➝ $135.00
2/18/2025	MRK Merck & Co., Inc.	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold	$128.00 ➝ $105.00
2/18/2025	MRNA Moderna	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sector Perform ➝ Sector Perform	$40.00 ➝ $40.00

(Data available from 4/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AMGN Amgen	$33.42B	4.93	$30.75 per share	9.98	$10.93 per share	28.08
BIIB Biogen	$9.68B	2.00	$21.68 per share	6.09	$114.71 per share	1.15
MRK Merck & Co., Inc.	$64.17B	3.43	$3.02 per share	28.82	$14.85 per share	5.86
MRNA Moderna	$3.20B	3.28	N/A	N/A	$28.33 per share	0.96
PFE Pfizer	$63.63B	2.19	$3.84 per share	6.38	$15.81 per share	1.55

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AMGN Amgen	$4.09B	$7.55	40.65	14.35	2.63	12.24%	176.32%	11.71%	5/1/2025 (Estimated)
BIIB Biogen	$1.63B	$11.19	11.80	8.00	1.51	16.87%	14.98%	8.76%	4/23/2025 (Estimated)
MRK Merck & Co., Inc.	$17.12B	$6.73	12.94	8.80	0.77	26.67%	45.35%	17.36%	4/24/2025 (Estimated)
MRNA Moderna	-$3.56B	-$9.28	N/A	N/A	N/A	-110.04%	-28.74%	-21.83%	5/1/2025 (Estimated)
PFE Pfizer	$8.03B	$1.41	17.39	8.09	0.64	12.62%	19.47%	8.09%	4/29/2025 (Estimated)

Latest MRNA, MRK, BIIB, PFE, and AMGN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
4/29/2025	N/A	PFE Pfizer	$0.67	N/A	N/A	N/A	$14.43 billion	N/A
4/24/2025	N/A	MRK Merck & Co., Inc.	$2.16	N/A	N/A	N/A	$15.59 billion	N/A
4/23/2025	N/A	BIIB Biogen	$3.59	N/A	N/A	N/A	$2.25 billion	N/A
2/12/2025	Q4 2024	BIIB Biogen	$3.43	$3.44	+$0.01	$1.83	$2.42 billion	N/A
2/4/2025	Q4 2024	AMGN Amgen	$5.04	$5.31	+$0.27	$1.16	$8.87 billion	N/A
2/4/2025	Q4 2024	MRK Merck & Co., Inc.	$1.85	$1.72	-$0.13	$1.48	$15.51 billion	$15.62 billion
2/4/2025	Q4 2024	PFE Pfizer	$0.48	$0.63	+$0.15	$0.07	$17.26 billion	$17.76 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AMGN Amgen	$9.52	3.10%	+8.53%	126.09%	14 Years
BIIB Biogen	N/A	N/A	N/A	N/A	N/A
MRK Merck & Co., Inc.	$3.24	3.72%	+5.73%	48.14%	14 Years
MRNA Moderna	N/A	N/A	N/A	N/A	N/A
PFE Pfizer	$1.72	7.01%	+2.50%	121.99%	16 Years

Latest MRNA, MRK, BIIB, PFE, and AMGN Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
3/4/2025	AMGN Amgen	quarterly	$2.38	3.05%	5/16/2025	5/16/2025	6/6/2025
1/28/2025	MRK Merck & Co., Inc.	quarterly	$0.81	3.32%	3/17/2025	3/17/2025	4/7/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AMGN Amgen	9.62	1.26	0.95
BIIB Biogen	0.27	1.35	0.90
MRK Merck & Co., Inc.	0.79	1.36	1.15
MRNA Moderna	N/A	3.67	3.62
PFE Pfizer	0.63	1.00	0.73

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AMGN Amgen	76.50%
BIIB Biogen	87.93%
MRK Merck & Co., Inc.	76.07%
MRNA Moderna	75.33%
PFE Pfizer	68.36%

Insider Ownership

Company	Insider Ownership
AMGN Amgen	0.69%
BIIB Biogen	0.16%
MRK Merck & Co., Inc.	0.09%
MRNA Moderna	11.00%
PFE Pfizer	0.06%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AMGN Amgen	28,000	537.21 million	533.50 million	Optionable
BIIB Biogen	8,720	146.38 million	146.14 million	Optionable
MRK Merck & Co., Inc.	69,000	2.53 billion	2.53 billion	Optionable
MRNA Moderna	3,900	386.62 million	324.40 million	Optionable
PFE Pfizer	83,000	5.67 billion	5.66 billion	Optionable

MRNA, MRK, BIIB, PFE, and AMGN Headlines

Recent News About These Companies

PFE Secures EU Nod for Expanded Use of RSV Vaccine Abrysvo

April 2 at 8:40 AM | zacks.com

Wall Street Says Sell US Market Rallies: Never Sell These 4 High-Yield Dividend Giants

April 2 at 7:47 AM | 247wallst.com

SevenBridge Financial Group LLC Sells 37,323 Shares of Pfizer Inc. (NYSE:PFE)

April 2 at 7:29 AM | marketbeat.com

Pfizer Inc. (NYSE:PFE) Position Boosted by Private Portfolio Partners LLC

April 2 at 6:43 AM | marketbeat.com

Te Ahumairangi Investment Management Ltd Reduces Position in Pfizer Inc. (NYSE:PFE)

April 2 at 6:35 AM | marketbeat.com

Columbia Asset Management Sells 28,637 Shares of Pfizer Inc. (NYSE:PFE)

April 2 at 6:34 AM | marketbeat.com

Massachusetts Financial Services Co. MA Boosts Holdings in Pfizer Inc. (NYSE:PFE)

April 2 at 6:34 AM | marketbeat.com

RFG Bristol Wealth Advisors LLC Invests $552,000 in Pfizer Inc. (NYSE:PFE)

April 2 at 6:33 AM | marketbeat.com

Groupama Asset Managment Reduces Stake in Pfizer Inc. (NYSE:PFE)

April 2 at 6:17 AM | marketbeat.com

StoneX Group Inc. Boosts Holdings in Pfizer Inc. (NYSE:PFE)

April 2 at 5:46 AM | marketbeat.com

Alliancebernstein L.P. Cuts Stake in Pfizer Inc. (NYSE:PFE)

April 2 at 5:18 AM | marketbeat.com

O Shaughnessy Asset Management LLC Sells 254,639 Shares of Pfizer Inc. (NYSE:PFE)

April 2 at 4:56 AM | marketbeat.com

2 Healthcare Stocks to Watch as JPMorgan Boosts Gilead Rating

April 1 at 7:49 PM | marketbeat.com

2 Healthcare Stocks to Watch as JPMorgan Boosts Gilead Rating

April 1 at 7:49 PM | marketbeat.com

Why Major Pharmaceutical Stocks Tumbled on Tuesday

April 1 at 7:09 PM | fool.com

Pfizer Stock (PFE) Faces Decline Amid Market Volatility

April 1 at 3:08 PM | gurufocus.com

Pfizer (PFE) Shows Potential for Continued Earnings Surprises

April 1 at 2:18 PM | gurufocus.com

Trump's tariffs are a new challenge for Big Pharma. Here are the best positioned stocks

April 1 at 2:01 PM | cnbc.com

Pfizer (NYSE:PFE) Shares Down 1.5% - Here's Why

April 1 at 1:54 PM | marketbeat.com

EU Approves Pfizer's ABRYSVO RSV Vaccine for Adults 18-59

April 1 at 1:49 PM | miragenews.com

Is Pfizer Inc. (PFE) the Most Undervalued Healthcare Stock to Buy According to Analysts?

April 1 at 1:49 PM | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Warren Buffett Swaps VOO for This Reliable Dividend Stock
By Sarah Horvath | March 7, 2025
View Warren Buffett Swaps VOO for This Reliable Dividend Stock
NVIDIA’s Soaring Energy Needs Make These 3 Nuclear Stocks a Buy
By Thomas Hughes | March 12, 2025
View NVIDIA’s Soaring Energy Needs Make These 3 Nuclear Stocks a Buy
BYD Unveils Ultra-Fast Charging—Will It Supercharge BYDDY Stock?
By Jeffrey Neal Johnson | March 21, 2025
View BYD Unveils Ultra-Fast Charging—Will It Supercharge BYDDY Stock?
Moderna: 4 Key Reasons the CEO Just Bought $5M in Shares
By Jea Yu | March 11, 2025
View Moderna: 4 Key Reasons the CEO Just Bought $5M in Shares
2 Healthcare Stocks to Watch as JPMorgan Boosts Gilead Rating
By Gabriel Osorio-Mazilli | April 1, 2025
View 2 Healthcare Stocks to Watch as JPMorgan Boosts Gilead Rating

MRNA, MRK, BIIB, PFE, and AMGN Company Descriptions

Amgen NASDAQ:AMGN

$306.92 -4.63 (-1.49%)

Closing price 04/1/2025 04:00 PM Eastern

Extended Trading

$306.06 -0.86 (-0.28%)

As of 08:58 AM Eastern

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Biogen NASDAQ:BIIB

$132.03 -4.81 (-3.52%)

Closing price 04/1/2025 04:00 PM Eastern

Extended Trading

$133.75 +1.72 (+1.30%)

As of 08:58 AM Eastern

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Merck & Co., Inc. NYSE:MRK

$87.08 -2.69 (-2.99%)

Closing price 04/1/2025 03:59 PM Eastern

Extended Trading

$87.32 +0.24 (+0.28%)

As of 09:00 AM Eastern

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Moderna NASDAQ:MRNA

$27.16 -1.19 (-4.20%)

Closing price 04/1/2025 04:00 PM Eastern

Extended Trading

$26.80 -0.36 (-1.31%)

As of 09:02 AM Eastern

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Pfizer NYSE:PFE

$24.52 -0.82 (-3.22%)

Closing price 04/1/2025 03:59 PM Eastern

Extended Trading

$24.52 0.00 (-0.02%)

As of 09:03 AM Eastern

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare MarketRank™

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest MRNA, MRK, BIIB, PFE, and AMGN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest MRNA, MRK, BIIB, PFE, and AMGN Earnings

Compare Dividends

Latest MRNA, MRK, BIIB, PFE, and AMGN Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

MRNA, MRK, BIIB, PFE, and AMGN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

MRNA, MRK, BIIB, PFE, and AMGN Company Descriptions

Amgen NASDAQ:AMGN

Biogen NASDAQ:BIIB

Merck & Co., Inc. NYSE:MRK

Moderna NASDAQ:MRNA

Pfizer NYSE:PFE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools